Cellect Biotechnology reports safety data from Phase I/II trial of ApoGraft
Cellect Biotechnology announced further data from a Phase I/II study of its ApoGraft technology. With half of the patients planned for the study having finished first month follow up, all such patients have shown 100% engraftment with no procedure related adverse events reported. The first three patients of the trial - cohort I - have completed the study period with full safety and tolerability. Cellect's ApoGraft technology aims to turn stem cell transplantations into a safe procedure by proper selection of the needed cells and elimination of the toxicity causing cells thereby reducing the associated severe side effects and consequently the outcome of the patients. The primary endpoint of the study is overall incidence, frequency and severity of adverse events potentially related to ApoGraft at 180 days from transplantation. Cellect is proceeding with enrolling and dosing the third cohort of the study.